About Generation Bio
Generation Bio is a company based in Cambridge (United States) founded in 2016 by Phillip Samayoa and Mark Angelino was acquired by XOMA Corporation in December 2025.. Generation Bio has raised $236.47 million across 3 funding rounds from investors including Fidelity Investments, T. Rowe Price and Farallon Capital Management. The company has 115 employees as of December 31, 2024. Generation Bio offers products and services including ctLNP-siRNA. Generation Bio operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Cambridge, United States
- Employees 115 as on 31 Dec, 2024
- Founders Phillip Samayoa, Mark Angelino
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Generation Bio Co.
-
Annual Revenue
$19.89 M236.92as on Dec 31, 2024
-
Net Profit
$-131.67 M-3.99as on Dec 31, 2024
-
EBITDA
$-73.41 M41.87as on Dec 31, 2024
-
Total Equity Funding
$236.47 M (USD)
in 3 rounds
-
Latest Funding Round
$111.47 M (USD), Series C
Jan 10, 2020
-
Investors
Fidelity Investments
& 10 more
-
Employee Count
115
as on Dec 31, 2024
-
Acquired by
XOMA Corporation
(Dec 15, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Generation Bio
Generation Bio is a publicly listed company on the NASDAQ with ticker symbol GBIO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Generation Bio
Generation Bio offers a comprehensive portfolio of products and services, including ctLNP-siRNA. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Delivers siRNA to T cells for treating autoimmune diseases
Unlock access to complete
Unlock access to complete
Leadership Team
8 people
Advisor Team
5 people
Founder Team
1 people
Chair Team
1 people
Unlock access to complete
Funding Insights of Generation Bio
Generation Bio has successfully raised a total of $236.47M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $111.47 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $111.5M
-
First Round
First Round
(04 Jan 2018)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2020 | Amount | Series C - Generation Bio | Valuation | T. Rowe Price | |
| Feb, 2018 | Amount | Series B - Generation Bio | Valuation | Fidelity Investments | |
| Jan, 2018 | Amount | Series A - Generation Bio | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Generation Bio
Generation Bio has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, T. Rowe Price and Farallon Capital Management. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life science and biotechnology sectors
|
Founded Year | Domain | Location | |
|
Multiple investment strategies are pursued by this hedge fund.
|
Founded Year | Domain | Location | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Generation Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Generation Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Generation Bio Comparisons
Competitors of Generation Bio
Generation Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Generation Bio
Frequently Asked Questions about Generation Bio
When was Generation Bio founded?
Generation Bio was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Where is Generation Bio located?
Generation Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Generation Bio?
Geoff McDonough is the current CEO of Generation Bio.
Is Generation Bio a funded company?
Generation Bio is a funded company, having raised a total of $236.47M across 3 funding rounds to date. The company's 1st funding round was a Series A of $25M, raised on Jan 04, 2018.
How many employees does Generation Bio have?
As of Dec 31, 2024, the latest employee count at Generation Bio is 115.
What is the annual revenue of Generation Bio?
Annual revenue of Generation Bio is $19.89M as on Dec 31, 2024.
What does Generation Bio do?
Generation Bio was founded in 2016 in Cambridge, United States, within the biotechnology sector. Non-viral gene therapies are provided for conditions such as phenylketonuria, hemophilia A, Wilson disease, Leber congenital amaurosis, and Stargardt disease. The Gene Wave technology enables optimal titration and re-dosing through closed-ended DNA. This ceDNA is packaged in lipid nanoparticles, which dissolve into cell cytoplasm and enter the nucleus to produce proteins.
Who are the top competitors of Generation Bio?
Generation Bio's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Generation Bio offer?
Generation Bio offers ctLNP-siRNA.
Is Generation Bio publicly traded?
Yes, Generation Bio is publicly traded on NASDAQ under the ticker symbol GBIO.
Who are Generation Bio's investors?
Generation Bio has 11 investors. Key investors include Fidelity Investments, T. Rowe Price, Farallon Capital Management, Atlas Venture, and XOMA Corporation.
What is Generation Bio's ticker symbol?
The ticker symbol of Generation Bio is GBIO on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.